Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.

التفاصيل البيبلوغرافية
العنوان:	Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
المؤلفون:	Ivanova M; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Porta FM; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., D'Ercole M; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Pescia C; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Sajjadi E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy., Cursano G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., De Camilli E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Pala O; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Mazzarol G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Venetis K; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Guerini-Rocco E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy., Viale G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy., Fusco N; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy. nicola.fusco@ieo.it.; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy. nicola.fusco@ieo.it.
المصدر:	Virchows Archiv : an international journal of pathology [Virchows Arch] 2024 Jan; Vol. 484 (1), pp. 3-14. Date of Electronic Publication: 2023 Sep 28.
نوع المنشور:	Journal Article; Review
اللغة:	English
بيانات الدورية:	Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Berlin ; New York : Springer International, c1994-
مواضيع طبية MeSH:	Receptor, ErbB-2/genetics , Breast Neoplasms/metabolism, Humans ; Female ; In Situ Hybridization, Fluorescence/methods ; Artificial Intelligence ; In Situ Hybridization ; Biomarkers, Tumor
مستخلص:	Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The trial focused on patients with metastatic breast cancer who were classified as "HER2-low," i.e., those with immunohistochemistry (IHC) HER2 1 + or 2 + and negative in situ hybridization (ISH) results. The study revealed that treating these patients with trastuzumab deruxtecan (T-DXd) instead of the oncologist's chosen chemotherapy led to outstanding improvements in survival. This has challenged the existing binary HER2 pathological classification system, which categorized tumors as either positive (overexpression/amplification) or negative, as per the ASCO/CAP 2018 guideline reaffirmed by ASCO/CAP 2023 guideline update. Given that DB-04 excluded patients with HER2 IHC score 0 status, the results of the ongoing DB-06 trial may shed further light on the potential benefits of T-DXd therapy for these patients. Roughly half of all breast cancers are estimated to belong to the HER2-low category, which does not represent a distinct or specific subtype of cancer. Instead, it encompasses a diverse group of tumors that exhibit clinical, morphological, immunohistochemical, and molecular variations. However, HER2-low offers a distinctive biomarker status that identifies a specific therapeutic regimen (i.e., T-DXd) linked to a favorable prognosis in breast cancer. This unique association emphasizes the importance of accurately identifying these tumors. Differentiating between a HER2 IHC score 0 and score 1 + has not been clinically significant until now. To ensure accurate classification and avoid misdiagnosis, it is necessary to adopt standardized procedures, guidelines, and specialized training for pathologists in interpreting HER2 expression in the lower spectrum. Additionally, the utilization of artificial intelligence holds promise in supporting this endeavor. Here, we address the current state of the art and unresolved issues in assessing HER2-low status, with a particular emphasis on the score 0. We explore the dilemma surrounding the exclusion of HER2-zero patients from potentially beneficial therapy based on traditional HER2 testing. Additionally, we examine the clinical context, considering that DB-04 primarily involved heavily pretreated late-stage metastatic breast cancers. We also delve into emerging evidence suggesting that extrapolating HER2-low status from the original diagnosis may lead to misleading results. Finally, we provide recommendations for conducting high-quality testing and propose a standardized pathology report in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. (© 2023. The Author(s).)
References:	(2020) Trastuzumab deruxtecan is effective in HER2-low breast cancer. Cancer Discov 10(4):488. https://doi.org/10.1158/2159-8290.cd-rw2020-030. Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E (2021) HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel) 13:2824. https://doi.org/10.3390/cancers13112824. (PMID: 10.3390/cancers1311282434198891) Ahn S, Woo JW, Lee K, Park SY (2020) HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 54:34–44. https://doi.org/10.4132/jptm.2019.11.03. (PMID: 10.4132/jptm.2019.11.0331693827) Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M (2021) The role of the pathologist in the next-generation era of tumor molecular characterization. Diagnostics 11:339. (PMID: 10.3390/diagnostics11020339336706997922586) Ballard M, Jalikis F, Krings G, Schmidt RA, Chen Y-Y, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, Allison KH (2017) ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol 30:227–235. https://doi.org/10.1038/modpathol.2016.175. (PMID: 10.1038/modpathol.2016.17527739440) Bianchi S, Caini S, Paglierani M, Saieva C, Vezzosi V, Baroni G, Simoni A, Palli D (2015) Accuracy and reproducibility of HER2 status in breast cancer using immunohistochemistry: a quality control study in Tuscany evaluating the impact of updated 2013 ASCO/CAP recommendations. Pathol Oncol Res 21:477–485. https://doi.org/10.1007/s12253-014-9852-0. (PMID: 10.1007/s12253-014-9852-025367072) Bonizzi G, Capra M, Cassi C, Taliento G, Pala O, Sajjadi E, Venetis K, Ivanova M, Monturano M, Renne G, Zattoni L, Guerini-Rocco E, Viale G, Orecchia R, Fusco N (2022) Biobank for translational medicine: standard operating procedures for optimal sample management. J Vis Exp. https://doi.org/10.3791/63950. (PMID: 10.3791/6395036533819) Bonizzi G, Zattoni L, Capra M, Cassi C, Taliento G, Ivanova M, Guerini-Rocco E, Fumagalli M, Monturano M, Albini A, Viale G, Orecchia R, Fusco N (2022) Standard operating procedures for biobank in oncology. Front Mol Biosci 9:967310. https://doi.org/10.3389/fmolb.2022.967310. (PMID: 10.3389/fmolb.2022.967310360900489459387) Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Peto R, Davies L, Dodwell D, McGale P, Pan H, Taylor C, Anderson S, Gelber R, Gianni L, Jacot W, Joensuu H, Moreno-Aspitia A, Piccart M, Press M, Romond E, Slamon D, Suman V, Berry R, Boddington C, Clarke M, Davies C, Duane F, Evans V, Gay J, Gettins L, Godwin J, James S, Liu H, MacKinnon E, Mannu G, McHugh T, Morris P, Read S, Straiton E, Wang Y, Crown J, de Azambuja E, Delaloge S, Fung H, Geyer C, Spielmann M, Valagussa P, Albain K, Arriagada R, Bartlett J, Bergsten-Nordström E, Bliss J, Brain E, Carey L, Coleman R, Cuzick J, Davidson N, Del Mastro L, Di Leo A, Dignam J, Dowsett M, Ejlertsen B, Francis P, Gnant M, Goetz M, Goodwin P, Halpin-Murphy P, Hayes D, Hill C, Jagsi R, Janni W, Loibl S, Mamounas EP, Martín M, Mukai H, Nekljudova V, Norton L, Ohashi Y, Pierce L, Poortmans P, Raina V, Rea D, Regan M, Robertson J, Rutgers E, Spanic T, Sparano J, Steger G, Tang G, Toi M, Tutt A, Viale G, Wang X, Whelan T, Wilcken N, Wolmark N, Cameron D, Bergh J, Pritchard KI, Swain SM (2021) Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 22:1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6. (PMID: 10.1016/S1470-2045(21)00288-6) Branco FP, Machado D, Silva FF, André S, Catarino A, Madureira R, Pinto JM, Godinho JP, Simões PD, Brito M, Casa-Nova M, Moreira AR, Passos-Coelho JL (2019) Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am J Transl Res 11:6110–6116. (PMID: 316325796789273) Brunelli M, Nottegar A, Bogina G, Caliò A, Cima L, Eccher A, Vicentini C, Marcolini L, Scarpa A, Pedron S, Brunello E, Knuutila S, Sapino A, Marchiò C, Bria E, Molino A, Carbognin L, Tortora G, Jasani B, Miller K, Merdol I, Zanatta L, Laurino L, Wirtanen T, Zamboni G, Marconi M, Chilosi M, Manfrin E, Martignoni G, Bonetti F (2015) Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. Am J Cancer Res 5:2212–2221. (PMID: 263282514548332) Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, Fusco N, Malapelle U, Fassan M (2022) FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint. J Pers Med 12:750. https://doi.org/10.3390/jpm12050750. (PMID: 10.3390/jpm1205075035629172) Chung C, Yeung VTY, Wong KCW (2022) Prognostic and predictive biomarkers with therapeutic targets in breast cancer: a 2022 update on current developments, evidence, and recommendations. J Oncol Pharm Pract 0(0). https://doi.org/10.1177/10781552221119797. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931. https://doi.org/10.1136/jclinpath-2014-202404. (PMID: 10.1136/jclinpath-2014-20240425012948) De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon YCS, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS (2018) Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget 9:20617–20630. https://doi.org/10.18632/oncotarget.25041. (PMID: 10.18632/oncotarget.25041297556765945519) de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimarães PT, Sá DDS, Simões MFE, Viana RL, Rocha FG, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Campos FAB, Sanches SM, de Lima VCC, Pondé NF (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190:155–163. https://doi.org/10.1007/s10549-021-06365-7. (PMID: 10.1007/s10549-021-06365-7) Diamantis N, Banerji U (2016) Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer 114:362–367. https://doi.org/10.1038/bjc.2015.435. (PMID: 10.1038/bjc.2015.435267420084815767) Dileep G, Gianchandani Gyani SG (2022) Artificial intelligence in breast cancer screening and diagnosis. Cureus 14:e30318. https://doi.org/10.7759/cureus.30318. (PMID: 10.7759/cureus.30318363817169650950) Ercolani C, Marchiò C, Di Benedetto A, Fabi A, Perracchio L, Vici P, Sperati F, Buglioni S, Arena V, Pescarmona E, Sapino A, Terrenato I, Mottolese M (2017) Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. J Exp Clin Cancer Res 36:143. https://doi.org/10.1186/s13046-017-0613-2. (PMID: 10.1186/s13046-017-0613-2290296405640946) Ergun Y, Ucar G, Akagunduz B (2023) Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis. Cancer Treat Rev 115:102538. https://doi.org/10.1016/j.ctrv.2023.102538. (PMID: 10.1016/j.ctrv.2023.10253836898351) Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL (2022) Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 8:1–4. https://doi.org/10.1001/jamaoncol.2021.7239. (PMID: 10.1001/jamaoncol.2021.7239351131608814969) Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell’Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE (2021) Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 11:2474–2487. https://doi.org/10.1158/2159-8290.Cd-20-1557. (PMID: 10.1158/2159-8290.Cd-20-1557339415928598376) Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, Demeo MK, Bardia A, Dell’Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE (2021) Impact of her2 heterogeneity on treatment response of early-stage her2-positive breast cancer: phase ii neoadjuvant clinical trial of t-dm1 combined with pertuzumab. Cancer Discov 11:2474–2487. https://doi.org/10.1158/2159-8290.CD-20-1557. (PMID: 10.1158/2159-8290.CD-20-1557339415928598376) Fusco N, Bosari S (2016) HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists. World J Gastroenterol 22:7926–7937. https://doi.org/10.3748/wjg.v22.i35.7926. (PMID: 10.3748/wjg.v22.i35.7926276722885028807) Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell’Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d’Amati G (2023) Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. Crit Rev Oncol/Hematol 190:104103. https://doi.org/10.1016/j.critrevonc.2023.104103. (PMID: 10.1016/j.critrevonc.2023.10410337595344) Fusco N, Malapelle U, Criscitiello C (2022) Editorial: Diagnosis and treatment of breast cancer in 2022: the rise of novel molecular biomarkers. Front Mol Biosci 9:1117323. https://doi.org/10.3389/fmolb.2022.1117323. (PMID: 10.3389/fmolb.2022.111732336660432) Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, Criscitiello C (2021) Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histol Histopathol 36:1235–1245. https://doi.org/10.14670/hh-18-376. Fusco N, Rizzo A, Costarelli L, Santinelli A, Cerbelli B, Scatena C, Macri E, Pietribiasi F, d’Amati G, Sapino A, Castellano I (2022) Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC). Pathologica 114:104–110. https://doi.org/10.32074/1591-951X-747. (PMID: 10.32074/1591-951X-747354147229248246) Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, Singer CF, Roitner F, Hager C, Andel J, Hubalek M, Knauer M, Greil R (2021) Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res : BCR 23:112. https://doi.org/10.1186/s13058-021-01492-x. (PMID: 10.1186/s13058-021-01492-x349061988670265) Giugliano F, Carnevale Schianca A, Corti C, Ivanova M, Bianco N, Dellapasqua S, Criscitiello C, Fusco N, Curigliano G, Munzone E (2023) Unlocking the resistance to anti-HER2 treatments in breast cancer: the issue of HER2 spatial distribution. Cancers (Basel) 15:1385. https://doi.org/10.3390/cancers15051385. (PMID: 10.3390/cancers1505138536900178) Hartung ML, Baber R, Herpel E, Specht C, Brucker DP, Schoneberg A, Winter T, Nussbeck SY (2021) Harmonization of biobank education for biobank technicians: identification of learning objectives. Biotech 10:7. (PMID: 10.3390/biotech10020007358228179336536) Hayat A, Carter EP, King HW, Ors A, Doe A, Teijeiro SA, Charrot S, Godinho S, Cutillas P, Mohammed H, Grose RP, Ficz G (2023) Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening. Dis Model Mech 16(2): dmm049894. https://doi.org/10.1242/dmm.049894. Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H (2022) The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29:234–241. https://doi.org/10.1007/s12282-021-01303-3. (PMID: 10.1007/s12282-021-01303-334622383) Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A (2019) Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 175:401–408. https://doi.org/10.1007/s10549-019-05173-4. (PMID: 10.1007/s10549-019-05173-430806922) Indini A, Rijavec E, Grossi F (2021) Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci 22:4774. https://doi.org/10.3390/ijms22094774. (PMID: 10.3390/ijms22094774339463108125530) Jacot W, Maran-Gonzalez A, Massol O, Sorbs C, Mollevi C, Guiu S, Boissière-Michot F, Ramos J (2021) Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers. Cancers (Basel) 13:6059. https://doi.org/10.3390/cancers13236059. (PMID: 10.3390/cancers1323605934885167) Jasani B, Huss R, Taylor CR (2021) Post-analytic phase: interpretation, scoring and reporting of biopsy results. In: Jasani B, Huss R, Taylor CR (eds) Precision cancer medicine: role of the pathologist. Springer International Publishing, Cham, pp 115–124. (PMID: 10.1007/978-3-030-84087-7_12) Jensen SG, Thomas PE, Christensen IJ, Balslev E, Hansen A, Høgdall E (2020) Evaluation of analytical accuracy of HER2 status in patients with breast cancer: comparison of HER2 GPA with HER2 IHC and HER2 FISH. Apmis 128:573–582. https://doi.org/10.1111/apm.13076. (PMID: 10.1111/apm.1307632860265) Keam SJ (2020) Trastuzumab deruxtecan: first approval. Drugs 80:501–508. https://doi.org/10.1007/s40265-020-01281-4. (PMID: 10.1007/s40265-020-01281-432144719) Lenicek Krleza J, Honovic L, Vlasic Tanaskovic J, Podolar S, Rimac V, Jokic A (2019) Post-analytical laboratory work: national recommendations from the Working Group for Post-analytics on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb) 29:020502. https://doi.org/10.11613/bm.2019.020502. (PMID: 10.11613/bm.2019.02050231223256) Lenicek Krleza J, Honovic L, Vlasic Tanaskovic J, Podolar S, Rimac V, Jokic A (2019) Post-analytical laboratory work: national recommendations from the Working Group for Post-analytics on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb) 29:020502–020502. https://doi.org/10.11613/BM.2019.020502. (PMID: 10.11613/BM.2019.02050231223256) Li S, Wu J, Huang O, He J, Chen W, Li Y, Chen X, Shen K (2022) Association of molecular biomarker heterogeneity with treatment pattern and disease outcomes in multifocal or multicentric breast cancer. Front Oncol 12:833093. https://doi.org/10.3389/fonc.2022.833093. (PMID: 10.3389/fonc.2022.833093358144169259989) Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M, Fusco N (2019) Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors. Int J Mol Sci 20(3):510. https://doi.org/10.3390/ijms20030510. (PMID: 10.3390/ijms20030510306910466386970) Loughran PA, Ross MA, St Croix CM (2022) Immunohistochemistry. Curr Protoc 2:e549. https://doi.org/10.1002/cpz1.549. (PMID: 10.1002/cpz1.54936102926) Lucas E, Jabbar SB, Molberg K, Fang Y, Xie X-J, Blacketer S, Sahoo S (2019) Comparison of Dako Hercep test and Ventana PATHWAY Anti-HER2 (4B5) tests and their correlation with fluorescent in situ hybridization in breast carcinoma. Appl Immunohistochem Mol Morphol 27:403–409. https://doi.org/10.1097/pai.0000000000000646. (PMID: 10.1097/pai.000000000000064631233398) Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 72:123–135. https://doi.org/10.1016/j.semcancer.2020.02.016. (PMID: 10.1016/j.semcancer.2020.02.01632112814) Mayr D, Heim S, Werhan C, Zeindl-Eberhart E, Kirchner T (2009) Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest™ (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH). Virchows Arch 454:241–248. https://doi.org/10.1007/s00428-009-0728-8. (PMID: 10.1007/s00428-009-0728-819169706) Memon R, Prieto Granada CN, Harada S, Winokur T, Reddy V, Kahn AG, Siegal GP, Wei S (2022) Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression/gene amplification in breast cancer in the modern age: a single institution experience and pooled literature review study. Clin Breast Cancer 22:e123–e133. https://doi.org/10.1016/j.clbc.2021.05.004. (PMID: 10.1016/j.clbc.2021.05.00434120846) Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, Dieci MV (2021) Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7:137. https://doi.org/10.1038/s41523-021-00343-4. (PMID: 10.1038/s41523-021-00343-4346423488511010) Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2203690. (PMID: 10.1056/NEJMoa22036903613000610561652) Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S (2020) Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol : Off J Am Soc Clin Oncol 38:1887–1896. https://doi.org/10.1200/JCO.19.02318. (PMID: 10.1200/JCO.19.02318) Morganti S, Ivanova M, Ferraro E, Ascione L, Vivanet G, Bonizzi G, Curigliano G, Fusco N, Criscitiello C (2022) Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. Cancer Drug Resist 5:971–980. https://doi.org/10.20517/cdr.2022.55. (PMID: 10.20517/cdr.2022.55366278959771738) Nicolò E, Boscolo Bielo L, Curigliano G, Tarantino P (2023) The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol 15:17588359231152842. https://doi.org/10.1177/17588359231152842. (PMID: 10.1177/17588359231152842368443879943960) Nitta H, Kelly BD, Allred C, Jewell S, Banks P, Dennis E, Grogan TM (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66:313–324. https://doi.org/10.1111/pin.12407. (PMID: 10.1111/pin.1240727061008) Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM (2023) Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol 9:500–510. https://doi.org/10.1001/jamaoncol.2022.7476. (PMID: 10.1001/jamaoncol.2022.7476368211259951099) Pisapia P, L’Imperio V, Galuppini F, Sajjadi E, Russo A, Cerbelli B, Fraggetta F, d’Amati G, Troncone G, Fassan M, Fusco N, Pagni F, Malapelle U (2022) The evolving landscape of anatomic pathology. Crit Rev Oncol Hematol 178:103776. https://doi.org/10.1016/j.critrevonc.2022.103776. (PMID: 10.1016/j.critrevonc.2022.10377635934262) Rüschoff J, Friedrich M, Nagelmeier I, Kirchner M, Andresen LM, Salomon K, Portier B, Sredni ST, Schildhaus HU, Jasani B, Grzelinski M, Viale G (2022) Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Arch. https://doi.org/10.1007/s00428-022-03378-5. (PMID: 10.1007/s00428-022-03378-5359709779636083) Rüschoff J, Nagelmeier I, Jasani B, Stoss O (2021) ISH-based HER2 diagnostics. Pathologe 42:62–68. https://doi.org/10.1007/s00292-020-00878-6. (PMID: 10.1007/s00292-020-00878-633346874) Sajjadi E, Frascarelli C, Venetis K, Bonizzi G, Ivanova M, Vago G, Guerini-Rocco E, Fusco N (2023) Computational pathology to improve biomarker testing in breast cancer: how close are we? Eur J Cancer Prev. https://doi.org/10.1097/cej.0000000000000804. (PMID: 10.1097/cej.000000000000080437038998) Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, Ivanova M, Fusco N (2023) Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci 3(10):1176309. https://doi.org/10.3389/fmolb.2023.1176309. (PMID: 10.3389/fmolb.2023.1176309) Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, Ivanova M, Fusco N (2023) Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci 10:1176309. https://doi.org/10.3389/fmolb.2023.1176309. (PMID: 10.3389/fmolb.2023.11763093707720110106673) Sajjadi E, Venetis K, Ivanova M, Fusco N (2022) Improving HER2 testing reproducibility in HER2-low breast cancer. Drug Resist 5:882–888. https://doi.org/10.20517/cdr.2022.29. (PMID: 10.20517/cdr.2022.29) Sajjadi E, Venetis K, Piciotti R, Gambini D, Blundo C, Runza L, Ferrero S, Guerini-Rocco E, Fusco N (2021) Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer 21:1152. https://doi.org/10.1186/s12885-021-08889-z. (PMID: 10.1186/s12885-021-08889-z347067038555186) Sapino A, Goia M, Recupero D, Marchio C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 21(3):129. https://doi.org/10.3389/fonc.2013.00129. (PMID: 10.3389/fonc.2013.00129) Sapino A, Goia M, Recupero D, Marchiò C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 3:129–129. https://doi.org/10.3389/fonc.2013.00129. (PMID: 10.3389/fonc.2013.00129237343453659312) Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7:1. https://doi.org/10.1038/s41523-020-00208-2. (PMID: 10.1038/s41523-020-00208-2333979687782714) Schrohl AS, Pedersen HC, Jensen SS, Nielsen SL, Brünner N (2011) Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 59:975–983. https://doi.org/10.1111/j.1365-2559.2011.04034.x. (PMID: 10.1111/j.1365-2559.2011.04034.x220924093263426) Scott M, Vandenberghe ME, Scorer P, Boothman A-M, Barker C (2021) Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. J Clin Oncol 39:1021–1021. https://doi.org/10.1200/JCO.2021.39.15_suppl.1021. (PMID: 10.1200/JCO.2021.39.15_suppl.1021) Sun H, Chen H, Crespo J, Tang G, Robinson M, Lim B, Şahin AA (2021) Clinicopathological features of breast cancer with polysomy 17 and its response to neoadjuvant chemotherapy. Eur J Breast Health 17:128–136. https://doi.org/10.4274/ejbh.galenos.2021.2021-2-9. (PMID: 10.4274/ejbh.galenos.2021.2021-2-9338701128025723) Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35–43. https://doi.org/10.1016/j.ejca.2021.12.022. (PMID: 10.1016/j.ejca.2021.12.02235032815) Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.2286. (PMID: 10.1001/jamaoncol.2022.2286357373679227690) Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G (2023) ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 34:645–659. https://doi.org/10.1016/j.annonc.2023.05.008. (PMID: 10.1016/j.annonc.2023.05.00837269905) Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M (2014) Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Panel. Appl Immunohistochem Mol Morphol 22(4):241–52. https://doi.org/10.3390/ijms20030510. (PMID: 10.3390/ijms20030510247140414206554) Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N (2022) HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 5(9). https://doi.org/10.3389/fmolb.2022.834651. Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, Criscitiello C, Fusco N (2021) Breast cancer with bone metastasis: molecular insights and clinical management. Cells 10(6):1377. https://doi.org/10.3390/cells10061377. (PMID: 10.3390/cells10061377341995228229615) Viale G, Fusco N (2021) Pathology after neoadjuvant treatment — how to assess residual disease. Breast. https://doi.org/10.1016/j.breast.2021.11.009. (PMID: 10.1016/j.breast.2021.11.009348100499097800) Viale G, Niikura N, Tokunaga E, Aleynikova O, Hayashi N, Sohn J, O’Brien C, Higgins G, Varghese D, James GD, Moh A, Scotto N (2022) Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. J Clin Oncol 40:1087–1087. https://doi.org/10.1200/JCO.2022.40.16_suppl.1087. (PMID: 10.1200/JCO.2022.40.16_suppl.1087) Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/jco.2013.50.9984. (PMID: 10.1200/jco.2013.50.998424101045) Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/jco.2018.77.8738. (PMID: 10.1200/jco.2018.77.873829846122) Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M (2018) HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract 14:437–441. https://doi.org/10.1200/jop.18.00206. (PMID: 10.1200/jop.18.0020629920138) Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984. (PMID: 10.1200/JCO.2013.50.998424101045) Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH (2023) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2023-0950-SA. (PMID: 10.5858/arpa.2023-0950-SA37303228) Yildiz-Aktas IZ, Dabbs DJ, Bhargava R (2012) The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 25:1098–1105. https://doi.org/10.1038/modpathol.2012.59. (PMID: 10.1038/modpathol.2012.5922460807) Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG (2022) HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. https://doi.org/10.1038/s41379-022-01019-5. (PMID: 10.1038/s41379-022-01019-5360884779926946) Zhang H, Katerji H, Turner BM, Hicks DG (2021) HER2-low breast cancers: new opportunities and challenges. Am J Clin Pathol 157(3):328–336. https://doi.org/10.1093/ajcp/aqab117. (PMID: 10.1093/ajcp/aqab117) Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG (2020) Applying the new guidelines of HER2 testing in breast cancer. Curr Oncol Rep 22:51. https://doi.org/10.1007/s11912-020-0901-4. (PMID: 10.1007/s11912-020-0901-432346807)
فهرسة مساهمة:	Keywords: Biomarkers; Breast cancer; HER2; HER2-low; Pathology report
المشرفين على المادة:	EC 2.7.10.1 (Receptor, ErbB-2) 0 (Biomarkers, Tumor)
تواريخ الأحداث:	Date Created: 20230928 Date Completed: 20240117 Latest Revision: 20240619
رمز التحديث:	20240619
مُعرف محوري في PubMed:	PMC10791807
DOI:	10.1007/s00428-023-03656-w
PMID:	37770765
قاعدة البيانات:	MEDLINE

Find this article in full text from Springer Verlag.

Full Text Finder

الوصف
تدمد:	1432-2307
DOI:	10.1007/s00428-023-03656-w